REQUEST A DEMO
Total
USD $0.00
Search more companies

Gencurix Inc. (South Korea)

Main Activities: Medicinal and Botanical Manufacturing
Full name: Gencurix Inc. Profile Updated: July 04, 2023
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English Download a sample report

Gencurix Inc. is engaged in developing and producing of medical instruments. The company offers products such as diagnostic test kits that use genetic material extracted from cancer tissues to help determine whether patients will need chemo radiotherapy. Gencurix Inc. was incorporated in 2011 ans is based in Seoul, South Korea.

Headquarters
15th Floor, 243, Digital-ro Guro-gu Seoul
Seoul; Seoul;

Contact Details: Purchase the Gencurix Inc. report to view the information.

Basic Information
Total Employees:
Purchase the Gencurix Inc. report to view the information.
Outstanding Shares:
Purchase the Gencurix Inc. report to view the information.
Registered Capital:
Purchase the Gencurix Inc. report to view the information.
Incorporation Date:
September 21, 2011
Key Executives
Purchase this report to view the information.
CEO
Purchase this report to view the information.
Non-Executive Independent Director
Purchase this report to view the information.
Auditor
Purchase this report to view the information.
Vice President
Purchase this report to view the information.
Vice President
Ownership Details
Purchase this report to view the information.
19.7%
Purchase this report to view the information.
7.5%
Purchase this report to view the information.
5.9%
Company Performance
Financial values in the chart are available after Gencurix Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
16.22%
Total operating revenue
16.22%
Operating profit (EBIT)
23.07%
EBITDA
27.47%
Net Profit (Loss) for the Period
26.26%
Total assets
-34.09%
Total equity
-82.22%
Operating Profit Margin (ROS)
182.08%
Net Profit Margin
584.77%
Return on Equity (ROE)
-352.21%
Debt to Equity Ratio
91.68%
Quick Ratio
-0.75%
Cash Ratio
-0.28%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?